4GB Stock Chart & Stats
€0.36
-€0.03(-2.73%)
At close: 4:00 PM EST
€0.36
-€0.03(-2.73%)
Day’s Range― - ―
52-Week Range€0.11 - €3.17
Previous CloseN/A
Volume0.00
Average Volume (3M)100.00
Market Cap
€60.45M
Enterprise Value€180.63
Total Cash (Recent Filing)€99.22M
Total Debt (Recent Filing)€202.93M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding488,846,700
10 Day Avg. Volume300
30 Day Avg. Volume100
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.96Price Target Upside165.60% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€31.93M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Signal (PROSERA Phase III)A statistically significant functional improvement in 6MWD demonstrates a durable clinical benefit signal relevant to regulators and prescribers. Persistent, measurable patient‑level improvement strengthens the NDA rationale, supports commercialization planning, and underpins long‑term product value if approved.
Robust Mechanistic Imaging (CT FRI) EvidenceMechanistic imaging showing structural reverse remodeling that correlates with clinical endpoints provides durable biologic validation of the drug's effect. These objective biomarkers can reduce regulatory uncertainty, bolster label claims, and aid payer discussions and targeted patient identification over the medium term.
Capital Restructuring To Reduce Near‑term Debt BurdenA materially reduced convertible face amount and extended maturities, if implemented, structurally improve solvency and lower immediate refinancing pressure. This creates more time to pursue NDA and commercialization milestones without an imminent maturity cliff, improving medium‑term financing flexibility.
Bears Say
Weakened Balance Sheet And Negative EquityNegative equity and a marked asset contraction indicate cumulative losses have eroded capitalization, increasing insolvency risk and reducing financial flexibility. Persistent leverage limits access to non‑dilutive funding, raises covenant/default concerns, and constrains the firm's ability to invest in commercialization or new programs.
High Cash Burn And Short RunwayVery large negative operating cash flow and limited cash reserves create an acute financing imperative. Ongoing burn forces dilutive financings or deep cost cuts, which can disrupt development plans and commercialization readiness. This constraint materially raises execution risk over the next 2–6 months.
Regulatory Uncertainty From Missed Prespecified AlphaFailing to meet the prespecified alpha increases FDA discretion and the chance of additional data requests or conditional approvals. That elevated regulatory risk can extend timelines, require confirmatory work or post‑marketing commitments, and complicate payer and partner decisions around commercialization.
Gossamer Bio News
4GB FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was €0.11 and its highest was €3.17 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is €60.45M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Aug 11, 2026 which is in 20 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on May 18, 2026. The company reported -€0.175 earnings per share for the quarter, missing the consensus estimate of -€0.146 by -€0.03.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.1.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 488,846,700 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -€0.175 in its last earnings report, missing expectations of -€0.146. Following the earnings report the stock price went down -13.475%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in DE:4GB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.96 (165.60% Upside)
€0.96 (165.60% Upside)
Blogger Sentiment
Bullish
DE:4GB Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.06%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
4GB Stock 12 Month Forecast
Average Price Target
€0.96
▲(165.60% Upside)